User profiles for H Sakamoto

Hirotaka Sakamoto

- Verified email at okayama-u.ac.jp - Cited by 4956

Hirotoshi Sakamoto

- Verified email at nagoya-u.jp - Cited by 4012

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal

…, A Tomida, N Fujita, T Mashima, H Sakamoto… - Cancer …, 2003 - Wiley Online Library
Recent progress in the development of molecular cancer therapeutics has revealed new
types of antitumor drugs, such as Herceptin, Gleevec, and Iressa, as potent therapeutics for …

Novel brain function: biosynthesis and actions of neurosteroids in neurons

K Tsutsui, K Ukena, M Usui, H Sakamoto… - Neuroscience …, 2000 - Elsevier
Peripheral steroid hormones act on brain tissues through intracellular receptor-mediated
mechanisms to regulate several important brain neuronal functions. Therefore, the brain is …

[PDF][PDF] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

H Sakamoto, T Tsukaguchi, S Hiroshima, T Kodama… - Cancer cell, 2011 - cell.com
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain
cancers, following gene alterations such as chromosomal translocation, amplification, or …

[HTML][HTML] A new protein containing an SH2 domain that inhibits JAK kinases

…, M Masuhara, M Yokouchi, R Suzuki, H Sakamoto… - Nature, 1997 - nature.com
… 78–180 of human JAB) in kinase buffer (50 mM HEPES, pH 7.5, 50 mM NaCl, 5 mM MgCl
2 , 5 mM MnCl 2 and 0.1 mM Na 3 VO 4 ) in thepresence or absence of 0.2 mM ATP for 2 h at …

Advantages of using both voxel-and surface-based morphometry in cortical morphology analysis: a review of various applications

…, S Konishi, Y Masutani, H Sakamoto… - Magnetic resonance in …, 2022 - jstage.jst.go.jp
In addition, we introduce two other recent methods as future directions for estimating cortical
morphological changes: a multi-modal parcellation method using structural and functional …

Highly controlled acetylene accommodation in a metal–organic microporous material

…, Y Kubota, RV Belosludov, TC Kobayashi, H Sakamoto… - Nature, 2005 - nature.com
… To elucidate the mechanism of high adsorption ability for C 2 H 2 molecules in complex 1,
we determined the structure of complex 1 with adsorbed C 2 H 2 molecules by the MEM (…

KIF5B-RET fusions in lung adenocarcinoma

…, K Yasuda, M Hiramoto, T Nammo, H Sakamoto… - Nature medicine, 2012 - nature.com
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET
oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from …

[HTML][HTML] The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop

H Yasukawa, H Misawa, H Sakamoto… - The EMBO …, 1999 - embopress.org
The Janus family of protein tyrosine kinases (JAKs) regulate cellular processes involved in
cell growth, differentiation and transformation through their association with cytokine receptors…

[PDF][PDF] Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

T Takano, Y Ohe, H Sakamoto, K Tsuta… - J Clin …, 2005 - mhlw-grants.niph.go.jp
… HART consisted of a total dose of 576 Gy in 36 fractions delivered over 15 days using
three-times daily fractions with a 4-h interval between fractions and an 8-h interval between on-…

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

…, Y Kaneoka, Y Shimizu, S Nakamori, H Sakamoto… - The Lancet, 2016 - thelancet.com
Background Although adjuvant chemotherapy with gemcitabine is standard care for resected
pancreatic cancer, S-1 has shown non-inferiority to gemcitabine for advanced disease. We …